Assessment of coagulation profile in patients with liver cirrhosis and atrial fibrillation

Authors

DOI:

https://doi.org/10.22141/2308-2097.55.1.2021.229432

Keywords:

liver cirrhosis, atrial fibrillation, hemostasis, standard coagulation parameters

Abstract

Background. The comorbid course of liver cirrhosis and atrial fibrillation causes higher levels of hospitalizations, mortality, and ischemic stroke. Theoretically, rebalanced state of hemostasis in patients with liver cirrhosis may shift towards hypercoagulation on the background of atrial fibrillation and provoke adverse clinical consequences. The purpose of the study was to assess abnormalities in primary, secondary hemostasis and fibrinolytic system in patients with liver cirrhosis and atrial fibrillation using standard laboratory coagulation parameters and to investigate their chan­ges depending on the stage of liver cirrhosis A, B, C according to Child-Pugh score. Materials and methods. A cross-sectional prospective study was conducted with the inclusion of 106 patients aged 42 to 83 years: group I (n = 70) included the patients with liver cirrhosis and atrial fibrillation, II (n = 36) consisted of subjects with liver cirrhosis, which were distributed depending on the Child-Pugh score stages of cirrhosis, and 20 healthy individuals. The levels of platelets, APTT, INR, PT, TT, fibrinogen, D-dimer were assessed on a Steellex M200 coagulometer. Statistical ana­lysis (IBM SPSS Statistics) was performed. Results. The platelets count in group I patients was reduced by 37.4 % ((200.00 ± 8.33) vs. (274.7 ± 3.4), p < 0.001), a prolonged APTT time by 38.6 % ((44.35 ± 1.39) vs. (32.01 ± 0.63), p < 0.001), PT by 73.5 % ((19.40 ± 0.87) vs. (11.18 ± 0.53), p < 0.001), TT by 2.07 times ((25.70 ± 1.31) vs. (12.40 ± 0.66), p < 0.001), the INR increased by 24.3 % ((1.38 ± 0.04) vs. (1.11 ± 0.01), p < 0.001). The fibrinogen level was 20.9 % higher ((4.17 ± 0.17) vs. (3.45 ± 0.11), p < 0.001) than in the control group and was 83.7 % higher ((4.17 ± 0.17) vs. (2.27 ± 0.13), p < 0.001) than in group II. The D-dimer level was 83 % higher than in control ((675.0 ± 22.3) vs. (368.80 ± 21.85), p < 0.001) and 44 % higher ((675.0 ± 22.3) vs. (469.00 ± 37.18), p < 0.001) compared with group II. Conclusions. In patients with liver cirrhosis and atrial fibrillation, the abnormalities of primary hemostasis are detected due to the decrease of platelet count on the background of portal hypertension. At the secondary stage of hemostasis, the indicators of external and internal coagulation mechanisms are prolonged due to the reduced synthesis of coagulation factors by the liver. A more intensive generation of fibrinogen is determined at the stage of compensated and subcompensated cirrhosis with a gradual decrease at the stage of decompensation. The high activity of the fibrinolytic system is observed due to an increase in the D-dimer levels, which may indicate a prothrombotic state in these patients.

Downloads

Download data is not yet available.

References

Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151-171. doi:10.1016/j.jhep.2018.09.014.

Chokesuwattanaskul R, Thongprayoon C, Bathini T, et al. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol. 2019 Apr;31(4):514-519. doi:10.1097/MEG.0000000000001315.

Chung MK, Eckhardt LL, Chen LY, et al; American Heart Association Electrocardiography and Arrhythmias Committee and Exercise, et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020 Apr 21;141(16):e750-e772. doi:10.1161/CIR.0000000000000748.

Darrat YH, Smer A, Elayi CS, et al. Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis. World J Cardiol. 2020 Jul 26;12(7):342-350. doi:10.4330/wjc.v12.i7.342.

Forkin KT, Colquhoun DA, Nemergut EC, Huffmyer JL. The Coagulation Profile of End-Stage Liver Disease and Considerations for Intraoperative Management. Anesth Analg. 2018 Jan;126(1):46-61. doi:10.1213/ANE.0000000000002394.

Harrison MF. The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. West J Emerg Med. 2018 Sep;19(5):863-871. doi:10.5811/westjem.2018.7.37893.

Kaski JC, Arrebola-Moreno AL. Inflamación y trombosis en la fibrilación auricular. Rev Esp Cardiol. 2011 Jul;64(7):551-3. doi:10.1016/j.recesp.2011.03.015. (in Spanish).

Khoury T, Ayman AR, Cohen J, Daher S, Shmuel C, Mizrahi M. The Complex Role of Anticoagulation in Cirrhosis: An Updated Review of Where We Are and Where We Are Going. Digestion. 2016;93(2):149-59. doi:10.1159/000442877.

Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017 Mar;14(3):195-203. doi:10.11909/j.issn.1671-5411.2017.03.011.

Munger TM, Wu LQ, Shen WK. Atrial fibrillation. J Biomed Res. 2014 Jan;28(1):1-17. doi:10.7555/JBR.28.20130191.

GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi:10.1016/S0140-6736(18)32203-7.

Sarin SK, Maiwall R. Global Burden Of Liver Disease: A True Burden on Health Sciences and Economies. World Gastroenterology Organisation. Available from: https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies.

Yang ZJ, Costa KA, Novelli EM, Smith RE. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost. 2014 Mar;20(2):169-78. doi:10.1177/1076029612461846.

Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis. Hepatology. 2020 Jun;71(6):2135-2148. doi:10.1002/hep.31201.

Published

2021-09-06

How to Cite

Baylo, A., Shipulin, V., Cherniavskyi, V., & Parunyan, L. (2021). Assessment of coagulation profile in patients with liver cirrhosis and atrial fibrillation. GASTROENTEROLOGY, 55(1), 21–25. https://doi.org/10.22141/2308-2097.55.1.2021.229432

Issue

Section

Original Researches